Ma Ying, Li Bole, Zhao Xiangqin, Lu Yi, Li Xuesong, Zhang Jin, Wang Yifei, Zhang Jie, Wang Lulu, Meng Shuai, Hao Jihui
Department of Pancreatic Cancer, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Tianjin's Clinical Research Center for Cancer, Tianjin Key Laboratory of Digestive Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin 300060, China.
Department of Pharmacy, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin's Clinical Research Center for Cancer, Tianjin 300060, China.
iScience. 2024 Aug 21;27(9):110739. doi: 10.1016/j.isci.2024.110739. eCollection 2024 Sep 20.
Mast cell tryptases, a family of serine proteases involved in inflammatory responses and cancer development, present challenges in structural characterization and inhibitor development. We employed state-of-the-art protein structure prediction algorithms to model the three-dimensional structures of tryptases α, β, δ, γ, and ε with high accuracy. Computational docking identified potential substrates and inhibitors, suggesting overlapping yet distinct activities. Tryptases β, δ, and ε were predicted to act on phenolic compounds, with β and ε additionally hydrolyzing cyanides. Tryptase δ may possess unique formyl-CoA dehydrogenase activity. Virtual screening revealed 63 compounds exhibiting strong binding to tryptase β (TPSB2), 12 exceeding the affinity of the known inhibitor. Notably, the top hit (3-chloro-4-methylbenzimidamide) displayed over 10-fold selectivity for tryptase β over other isoforms. Our integrative approach combining protein modeling, functional annotation, and molecular docking provides a framework for characterizing tryptase isoforms and developing selective inhibitors of therapeutic potential in inflammatory and cancer conditions.
肥大细胞类胰蛋白酶是一类参与炎症反应和癌症发展的丝氨酸蛋白酶,在结构表征和抑制剂开发方面面临挑战。我们采用了最先进的蛋白质结构预测算法,以高精度对类胰蛋白酶α、β、δ、γ和ε的三维结构进行建模。计算对接确定了潜在的底物和抑制剂,表明它们具有重叠但又不同的活性。预测类胰蛋白酶β、δ和ε作用于酚类化合物,β和ε还能额外水解氰化物。类胰蛋白酶δ可能具有独特的甲酰辅酶A脱氢酶活性。虚拟筛选发现63种化合物与类胰蛋白酶β(TPSB2)具有强结合力,其中12种超过了已知抑制剂的亲和力。值得注意的是,排名第一的化合物(3-氯-4-甲基苯甲酰胺)对类胰蛋白酶β的选择性比对其他同工型高10倍以上。我们结合蛋白质建模、功能注释和分子对接的综合方法,为表征类胰蛋白酶同工型以及开发在炎症和癌症病症中具有治疗潜力的选择性抑制剂提供了一个框架。